Symbol="FATE"
AssetType="Common Stock"
Name="Fate Therapeutics Inc"
Description="Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders globally. The company is headquartered in San Diego, California."
CIK="1434316"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="438795000"
EBITDA="-247323008"
PERatio="None"
PEGRatio="0"
BookValue="4.863"
DividendPerShare="0"
DividendYield="0"
EPS="-2.39"
RevenuePerShareTTM="1.407"
ProfitMargin="-1.716"
OperatingMarginTTM="-1.918"
ReturnOnAssetsTTM="-0.22"
ReturnOnEquityTTM="-0.423"
RevenueTTM="136866000"
GrossProfitTTM="-224154000"
DilutedEPSTTM="-2.39"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="2.203"
AnalystTargetPrice="8.16"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="20.01"
PriceToBookRatio="2.883"
EVToRevenue="15.93"
EVToEBITDA="-3.697"
Beta="1.483"
num_52WeekHigh="37.13"
num_52WeekLow="4.02"
num_50DayMovingAverage="5.08"
num_200DayMovingAverage="9.72"
SharesOutstanding="98384000"
DividendDate="None"
ExDividendDate="None"
symbol="FATE"
open="4.51"
high="4.55"
low="4.38"
price="4.46"
volume="1322938.00"
latest_trading_day="2023-07-21"
previous_close="4.45"
change="0.01"
change_percent="0.2247%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="98"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="2"
Volume_recent_avg="2518379"
Change_recent_avg="-0.02"
Delta_recent_avg="0.36"
Variance_recent_avg="0.18"
Change_ratio_recent_avg="-0.53"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="2"
Aroon_momentum_negative="98"
image_negative_thumbnail_id_1="1152"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0185.jpeg"
image_negative_thumbnail_id_2="142"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0034.jpeg"
image_neutral_thumbnail_id_1="546"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0053.jpeg"
image_neutral_thumbnail_id_2="553"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0046.jpeg"
image_positive_thumbnail_id_1="966"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0128.jpeg"
image_positive_thumbnail_id_2="607"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0101.jpeg"
image_professor_thumbnail_id_1="1187"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0021.jpeg"
image_professor_thumbnail_id_2="1203"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0037.jpeg"
